Aclarion, Inc. (NASDAQ:ACON – Get Free Report) saw a significant decrease in short interest in August. As of August 31st, there was short interest totaling 24,767 shares, a decrease of 60.0% from the August 15th total of 61,992 shares. Based on an average daily volume of 83,475 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.9% of the company’s shares are short sold.
Analyst Upgrades and Downgrades
ACON has been the topic of several research reports. Weiss Ratings upgraded Aclarion from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, August 5th. Wall Street Zen raised shares of Aclarion from a “sell” rating to a “hold” rating in a research note on Saturday, June 20th. Finally, Ascendiant Capital Markets increased their target price on shares of Aclarion from $7.00 to $7.50 and gave the stock a “buy” rating in a report on Friday, May 29th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $7.50.
Check Out Our Latest Analysis on Aclarion
Aclarion Stock Up 2.4%
Aclarion (NASDAQ:ACON – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.07). Aclarion had a negative net margin of 10,948.81% and a negative return on equity of 59.34%. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. On average, sell-side analysts expect that Aclarion will post -4.51 EPS for the current year.
Insider Buying and Selling
In other news, Director Ryan Bond acquired 21,122 shares of Aclarion stock in a transaction on Thursday, August 13th. The shares were bought at an average cost of $2.37 per share, for a total transaction of $50,059.14. Following the acquisition, the director directly owned 76,122 shares of the company’s stock, valued at $180,409.14. This trade represents a 38.40% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. In the last quarter, insiders acquired 51,863 shares of company stock worth $125,670. Company insiders own 0.01% of the company’s stock.
About Aclarion
Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc and changed its name to Aclarion, Inc in December 2021.
Featured Articles
- Five stocks we like better than Aclarion
- Rocket Lab Tackles a Supply Chain Bottleneck as the Stock Hunts for a Bottom. Time to Buy?
- Optical Cable Corporation Is Starting to Get the Market’s Attention
- Oil Above $100 Is Creating a New Opportunity Beyond the Major Producers
- Is Nike’s Index Demotion a Warning or a Buying Opportunity?
Receive News & Ratings for Aclarion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclarion and related companies with MarketBeat.com's FREE daily email newsletter.
